Stylized illustration of a liver with reduced inflammation due to BATF interference.

Decoding Hepatitis B: How Blocking a Key Protein Could Ease Liver Inflammation

Rhea Morgan monogram
Rhea Morgan in Health & Wellness October 2026 • 4 min read.

"New research explores how interfering with BATF, a key protein, can help reduce liver damage in Hepatitis B virus transgenic mice, offering potential insights for future treatments."


Hepatitis B is a widespread health concern, affecting millions globally and leading to serious liver diseases. While the virus itself doesn't directly harm the liver, the body's immune response to the infection can cause significant inflammation and damage.

A key player in this immune response is a type of immune cell called Th17. These cells release substances that contribute to inflammation, and their activity is often elevated in chronic Hepatitis B infections. Scientists are working to understand how to regulate Th17 cell activity to reduce liver damage.

Now, research is shedding light on the role of a protein called BATF in driving Th17 cell activity in Hepatitis B. A new study explores how blocking BATF could help to reduce Th17 activity, and consequently, the inflammation in the liver. Let's delve into the findings and what they could mean for future Hepatitis B treatments.

AI Search Multiple angles on this topic

Hepatitis B in a Global Health Context

WHO’s Global hepatitis report 2026 says viral hepatitis remains a leading global health problem despite the availability of a highly effective hepatitis B vaccine since the 1990s and effective antiviral treatments for chronic hepatitis B. The report says hepatitis B and C together account for more than 95% of deaths related to viral hepatitis. In the United States, CDC’s HepTracker provides case-surveillance and viral-hepatitis-related mortality data for hepatitis A, B, and C to help track trends and inform public health programs.

BATF's Role in Hepatitis B Inflammation: An Explainer

Stylized illustration of a liver with reduced inflammation due to BATF interference.

The study, published in Digestive Diseases and Sciences, used Hepatitis B virus transgenic mice to investigate the effects of blocking BATF. These mice are engineered to carry the Hepatitis B virus and develop chronic liver inflammation, mimicking the human disease.

Researchers experimented with different approaches to reduce BATF activity in these mice, including using a technique called shRNA interference. shRNA interferes with the production of BATF, effectively 'silencing' the gene. They also tested the effects of combining BATF interference with entecavir, a common antiviral drug used to treat Hepatitis B.

The study revealed several key findings:
  • HBV infection significantly increased BATF expression and promoted Th17 cell activation.
  • BATF interference reduced the proportion of Th17 cells and serum IL-17 and IL-22 concentrations.
  • BATF interference significantly impeded the proliferation of Th17 cells and secretion of IL-17 and IL-22 while alleviating hepatic lesions.
  • HBV core antigen (HBcAg) concentration, BATF mRNA, and Th cell proportions all had significantly positive correlations.
AI Search Multiple angles on this topic

BATF and Inflammation-Related Research

A study of sepsis-associated liver injury describes guanylate-binding protein 5 (GBP-5) as part of cell-autonomous immunity and as associated with inflammation. Separately, a study cited by Chen et al. (2019) reported elevated BATF mRNA and protein in liver tissue from HBV-transgenic mice, alongside higher serum Th17 cells and the cytokines IL-17 and IL-22 than in controls. Another article reports that HBV affects stem-cell differentiation, with consequences for liver-tissue repair and regeneration. A 2026 review examines BATF’s role in the development and exhaustion of CD8+ T cells and its potential as a target in antitumor immunotherapy.

Evidence and Limits in BATF Studies

The listed studies investigate BATF in relation to Th17 differentiation and inflammatory responses, including in HBV-transgenic mice. One study describes using normal mice assigned to control, shRNA-scramble, and shRNA-BATF groups, and also examining HBV-transgenic mice. A separate study included 60 chronic hepatitis B patients, 22 patients with acute-on-chronic hepatitis B liver failure, and 17 healthy controls, and measured peripheral and intrahepatic BATF expression. The supplied source descriptions do not report the studies’ outcomes, so they do not establish from this information whether BATF interference improves clinical outcomes in people.

Different HBV Research Questions

The listed sources address distinct questions and do not provide a direct comparison of BATF inhibition with other HBV treatments. One cell study reports that combinations of the psiHBV4 vector with PgS2 or PgS3 significantly inhibited HBsAg and HBeAg expression compared with controls (P < 0.05), measuring expression in cell-disruption liquid and culture supernatant after 24 hours. Another source describes testing HBsAg and HBcAg in renal biopsies from 50 people with HBV-associated glomerulonephritis and 20 controls with non-HBV-associated glomerulonephritis. A third reports that HBsAg and HBcAg often coexisted in the same hepatocyte in chronic liver disease.

The results showed that blocking BATF led to a decrease in Th17 cell activity and reduced signs of liver inflammation. This suggests that BATF plays a significant role in driving the inflammatory response in Hepatitis B. Interestingly, blocking BATF did not reduce the amount of virus in the mice, suggesting that its primary effect is on the immune system rather than the virus itself.

What This Means for Future Hepatitis B Treatments

This research provides valuable insights into the complex interplay between the immune system and Hepatitis B. By identifying BATF as a key regulator of inflammation, it opens the door for new therapeutic strategies that target this protein.

AI Search Multiple angles on this topic

Barriers to Hepatitis B Elimination

A review reports that metabolic dysfunction-associated fatty liver disease (MAFLD) has become more prevalent among the general population and people with chronic hepatitis B worldwide, and notes fatty liver disease as a risk factor for adverse liver outcomes. Another article says substantial challenges remain in achieving the goal of eliminating HBV infection by 2030. WHO’s 2025 information sheet presents global and country-level progress on hepatitis B and C elimination against its 2025 and 2030 targets. A 2025 article calls for addressing financial, social, and systemic barriers to progress against viral hepatitis.

While the study was conducted in mice, the findings suggest that similar approaches could be beneficial in humans with chronic Hepatitis B. Future research will need to explore how to safely and effectively block BATF in humans and whether this approach can improve long-term outcomes for patients.

Ultimately, understanding and modulating the immune response in Hepatitis B is crucial for developing more effective treatments that can reduce liver damage and prevent the progression to serious liver diseases. This study highlights the potential of BATF as a therapeutic target in the fight against Hepatitis B.

How Th17 measures vary across patient groups

  • 37.9%Serum IL-17 was reported as 37.9% higher in chronic hepatitis B than in normal controls; the reported increases differed across the other liver-disease groups.[1]

What BATF-related evidence can-and cannot-show

Th17 cells can promote inflammation, but their capacity to recruit neutrophils and support antiviral CD8+ T-cell responses also points to potentially protective functions. Reducing this cell activity therefore does not, by itself, establish the overall effect on antiviral immunity.[2] [3]

The described mouse models differ substantially from human HBV infection, and persistent replication models may lack liver inflammation and immune-cell recruitment. Those features constrain how directly model results can be applied to human disease.[4]

How related HBV findings frame the question

A separate intervention involving stem-cell transplantation in cirrhotic patients reported improved liver function alongside decreases in Th17 cells and inflammatory cytokines. Because that intervention differs from BATF interference, it does not directly compare the approaches.[5]

Later sources cite Chen et al. for elevated BATF and Th17-related measures in HBV-transgenic mice, while another citation links HBV to altered stem-cell differentiation and liver repair. These citations place the BATF finding alongside broader questions about tissue recovery, but do not establish that BATF blocking improves repair.[6] [7]

Other evidence describes inflammation-related signals as part of liver fibrosis pathways, and reports that HBV transcripts in some mouse models are driven by constitutively active promoters rather than viral promoters. These model features and processes make it important to distinguish reduced inflammatory measures from demonstrated changes in fibrosis or viral control.[8] [9]

What remains unresolved about BATF and HBV

  • Would changing BATF affect antiviral T-cell support as well as inflammatory activity, given Th17 cells’ described roles in both processes?[2] [10]
  • Would BATF-related changes in a mouse model translate to human viral hepatitis, where the available evidence on IL-22 is limited and model systems have important differences?[4] [11]
  • Could changes in inflammatory activity alter liver repair or fibrosis, given the described links between HBV, stem-cell differentiation, and inflammatory pathways?[7] [9]

Sources

  1. Expression of Interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection (pmc.ncbi.nlm.nih.gov)
  2. CD4+ T Cells in Chronic Hepatitis B and T Cell-Directed Immunotherapy (pmc.ncbi.nlm.nih.gov)
  3. Intrahepatic TH17/TReg Cells in Homeostasis and Disease—It’s All About the Balance (pmc.ncbi.nlm.nih.gov)
  4. In Vivo Mouse Models for Hepatitis B Virus Infection and Their Application (pmc.ncbi.nlm.nih.gov)
  5. Immunity and Fibrogenesis: The Role of Th17/IL-17 Axis in HBV and HCV-induced Chronic Hepatitis and Progression to Cirrhosis (www.frontiersin.org)
  6. The value of fibroblast growth factor 21 (FGF21) promoter methylation in the repair and regeneration during the course of chronic hepatitis B (2025)
  7. Exploring the active ingredients and mechanisms of Liujunzi decoction in treating hepatitis B: a study based on network pharmacology, molecular docking, and molecular dynamics simulations (2024)
  8. In Vivo Model Systems for Hepatitis B Virus Research (pmc.ncbi.nlm.nih.gov)
  9. Insights into the impact of hepatitis B virus on hepatic stellate cell activation (pmc.ncbi.nlm.nih.gov)
  10. Batf coordinates multiple aspects of B and T cell function required for normal antibody responses (pmc.ncbi.nlm.nih.gov)
  11. Emerging Role of Interleukin 22 in Hepatitis B Virus Infection: a Double-edged Sword (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1007/s10620-018-5392-x, Alternate LINK

Title: Batf Interference Blocks Th17 Cell Differentiation And Inflammatory Response In Hepatitis B Virus Transgenic Mice

Subject: Gastroenterology

Journal: Digestive Diseases and Sciences

Publisher: Springer Science and Business Media LLC

Authors: Long-Yan Chen, Xiao-Peng Fan, Yu-Chen Fan, Jing Zhao, Shuai Gao, Feng Li, Zhao-Xia Qi, Kai Wang

Published: 2018-11-29

Everything You Need To Know

1

What is Hepatitis B?

Hepatitis B is a viral infection that affects the liver, leading to inflammation and potential long-term damage. While the virus itself doesn't directly harm the liver, the body's immune response to the infection causes significant inflammation. This inflammation is a key factor in the progression of liver diseases associated with Hepatitis B.

2

What is the role of BATF in Hepatitis B?

BATF, or 'B-cell activating transcription factor,' is a protein identified as a key regulator of inflammation in the context of Hepatitis B. The research showed that HBV infection significantly increased BATF expression and promoted Th17 cell activation. By blocking BATF, the study observed a reduction in Th17 cell activity and decreased signs of liver inflammation. This suggests that BATF plays a significant role in driving the inflammatory response in Hepatitis B.

3

What are Th17 cells and how are they related to Hepatitis B?

Th17 cells are a type of immune cell that plays a key role in the immune response to Hepatitis B. These cells release substances that contribute to inflammation, and their activity is often elevated in chronic Hepatitis B infections. Blocking BATF led to a decrease in Th17 cell activity and reduced signs of liver inflammation.

4

How was the study conducted?

The study used Hepatitis B virus transgenic mice, which are engineered to carry the Hepatitis B virus and develop chronic liver inflammation. Researchers experimented with different approaches to reduce BATF activity in these mice, including using shRNA interference, which interferes with the production of BATF, effectively 'silencing' the gene. They also tested the effects of combining BATF interference with entecavir, a common antiviral drug.

5

What are the potential implications of this research for future treatments?

The research suggests that targeting BATF could be a promising strategy for managing Hepatitis B. Blocking BATF reduces Th17 cell activity and liver inflammation, which could lead to better outcomes for patients. By understanding the role of BATF, scientists can develop new treatments that specifically target the inflammatory response, potentially improving liver health and reducing the progression of liver diseases associated with Hepatitis B. This approach focuses on managing the immune response rather than directly attacking the virus itself.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.